Breaking News

FDA Grants Orphan Drug Designation for Brain Cancer Drug Berubicin

Accelerates its development to treat malignant gliomas and provides CNS with the potential for market exclusivity.

By: Contract Pharma

Contract Pharma Staff

CNS Pharmaceuticals Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, have announced that the FDA has granted Orphan Drug Designation (ODD) for its lead product Berubicin for the treatment of malignant gliomas.   “We are pleased to receive Orphan Drug Designation for Berubicin, our lead candidate. The designation provides Berubicin with a special status that can accelerate its de...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters